ArticleBMC psychiatry2026
Elevated serum calprotectin levels in major depressive disorder: no evidence of association with S100A9 rs3014866 polymorphism.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMajor depressive disorder (MDD) has been increasingly associated with low-grade inflammation, with neutrophils playing a central role. Calprotectin is a mainly neutrophil-derived inflammatory mediator. We investigated whether serum calprotectin levels are higher in patients with MDD than in healthy controls and whether the S100A9 rs3014866 polymorphism is associated with serum calprotectin levels and with MDD.
methodsWe enrolled 66 patients with major depressive disorder (MDD) and 54 healthy controls. Depressive symptoms were assessed using the 17-item Hamilton Depression Rating Scale (HAM-D). Fasting venous blood samples were collected to measure serum calprotectin and to genotype the S100A9 rs3014866 polymorphism.
resultsSerum calprotectin levels were higher in patients with MDD than in healthy controls (2.18 ± 1.33 vs. 1.05 ± 0.55 µg/mL; p < 0.001). Serum calprotectin levels were positively correlated with HAM-D scores among patients with MDD (rs = 0.314, p = 0.010). The S100A9 rs3014866 genotype distribution was in Hardy-Weinberg equilibrium. Genotype and allele frequencies did not differ significantly between patients with MDD and healthy controls, and serum calprotectin levels did not differ significantly across genotype groups under the tested inheritance models.
conclusionsThese findings suggest that serum calprotectin may reflect inflammatory processes associated with MDD and that its potential role as a biomarker warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.